Aims To evaluate potential differences between PF\05280586 and rituximab sourced from europe (rituximab\EU) and USA (rituximab\US) in clinical response (Disease Activity Rating in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity assessment of PF\05280586. tracked the central tendency and distribution of observations well. Simply no true stage… Continue reading Aims To evaluate potential differences between PF\05280586 and rituximab sourced from